Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years old~* Sepsis \[ ≥2 Systemic Inflammatory Response Syndrome (SIRS) Criteria AND known or suspected infection\]~* Muscle weakness \[Medical Research Council sum score \<48/60 or handgrip strength \<11 kg in men and \<7 kg in women\]~* Obey Commands \[Score for DeJonghe Awakening Score of ≥3/5\]~Exclusion Criteria:~* Severe renal insufficiency \[Creatinine Clearance \<30 mL/min - or receiving dialysis\]~* Acute infectious or auto-immune hepatitis, acute liver failure or a history of cirrhosis without liver transplant~* History of psychosis~* Bradycardia, or 2nd or 3rd degree Atrio-Ventricular block without pacemaker~* History of valvular heart disease without valve replacement~* History of priapism~* Pre-existing cognitive impairment~* Receiving drugs with serotonergic effects and/or CYP2D6 substrates which cannot be substituted stopped or titrated.~* Receiving Sulfonylurea medication at the time of the study~* Prior neuromuscular or central nervous system disease, including pre-existing neuropathy~* Inability to perform study's muscle strength assessments based on patient's baseline status prior to hospital admission~* Unable to receive, or unlikely to absorb study drug (e.g. bowel obstruction, ischemia, or infarction; short gut syndrome)~* Body mass index \>40~* Patient not expected to survive \>4 days~* Pregnancy or lactation~* Allergy to lorcaserin or lorcaserin taken in the prior 7 days~* Enrolled in another interventional drug or physical rehabilitation trial~* Physician declines for patient to be enrolled~* Patient or proxy declines consent~* Unable to reach proxy for consent~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
- Control (Type: PLACEBO_COMPARATOR): Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).